Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
Case 5: Is There a Role for IO-Based Therapy in KRAS-Mutated NSCLC? What About Patients With Co-mutations in STK11 or KEAP1?
Case 5: Is There a Role for IO-Based Therapy in KRAS-Mutated NSCLC? What About Patients With Co-mutations in STK11 or KEAP1?
Case 3: In a PD-L1 Negative Patient, Is There Any Benefit to Using Single Agent IO/Chemotherapy or Dual Agent IO/ Chemotherapy?
Case 3: In a PD-L1 Negative Patient, Is There Any Benefit to Using Single Agent IO/Chemotherapy or Dual Agent IO/ Chemotherapy?
Case 2: In a Patient With PD-L1 1–49%, Should I Use Single Agent IO or Combination IO?
Case 2: In a Patient With PD-L1 1–49%, Should I Use Single Agent IO or Combination IO?
Case 4: In Patients Ineligible for Platinum-Based Chemotherapy, What Is the Ideal IO-Based Approach?
Case 4: In Patients Ineligible for Platinum-Based Chemotherapy, What Is the Ideal IO-Based Approach?
What’s the Consensus on Cardiorenal Protection for CKD in T2D?
What’s the Consensus on Cardiorenal Protection for CKD in T2D?
Taking Command of the Treatment of ESA-Refractory, Transfusion-dependent LR-MDS
Taking Command of the Treatment of ESA-Refractory, Transfusion-dependent LR-MDS
Applying Evidence to Practice: What Can We Learn from Recent Clinical Trials of IV Iron Use in HF?
Applying Evidence to Practice: What Can We Learn from Recent Clinical Trials of IV Iron Use in HF?
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Emergency Medicine Module
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Emergency Medicine Module
Patient-Centered Communications and Shared Decision-Making in the Management of Obesity
Patient-Centered Communications and Shared Decision-Making in the Management of Obesity
Can You Use a Dual Checkpoint Inhibitor Regimen in an Unfit Patient With BRAF WT Metastatic Melanoma?
Can You Use a Dual Checkpoint Inhibitor Regimen in an Unfit Patient With BRAF WT Metastatic Melanoma?
Frontline Treatment: A Patient With BRAF WT Metastatic Melanoma - What Is the Optimal ICI Regimen?
Frontline Treatment: A Patient With BRAF WT Metastatic Melanoma - What Is the Optimal ICI Regimen?
How Does Symptom Severity Influence Choice of Frontline Therapy for a Patient with BRAF-Mutated Metastatic Melanoma?
How Does Symptom Severity Influence Choice of Frontline Therapy for a Patient with BRAF-Mutated Metastatic Melanoma?